SCHAUMBURG, Ill., July 7, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of levofloxacin injection in 5% dextrose, the generic form of the antibacterial Levaquin®, in three ready-to-use premix bag strengths. According to 2010 IMS data, the U.S. market for levofloxacin approximated $156 million.
"The launch of levofloxacin represents our fourth product launched at patent expiry and the addition of another significant product to our anti-infective portfolio," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "As with other products in our anti-infective portfolio, levofloxacin injection is widely used because of its efficacy on wide variety of bacterial infections. In addition, our premix, ready-to-use levofloxacin injection offering features our PreventIV Measures packaging and labeling, designed to aid in the reduction of medication errors."
About Levofloxacin Injection in 5% Dextrose
Levofloxacin is a fluoroquinolone antibacterial indicated in adults ≥ 18 years of age with infections caused by designated, susceptible bacteria including: nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, pyelonephritis. Additionally, levofloxacin is also indicated for inhalational anthrax (post exposure), however, has not been tested in humans for post-exposure prevention of inhalational anthrax. Please see DOSAGE and ADMINISTRATION for complete details.
The package insert, which is available at www.SagentPharma.com, contains detailed information about the indications, complete side effect profile, boxed warnings and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent operates a global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, which quickly yields an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
Forward-Looking Statement
This press release contains a number of forward-looking statements. Words, and variations of words such as "expect," "goals," "plans," "believe," continue," "may," "will," and similar expressions are intended to identify our forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those indicated in our forward-looking statements. Please also see our risk factors, as they may be amended from time to time, set forth in our filings with the SEC, including the IPO prospectus filed by Sagent on April 21, 2011 and our most recent 10-Q. Sagent disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.